Takaya Ikeda

Takaya Ikeda

Auto-generated profile, based on publicly available information

Takaya Ikeda

Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 September 2018 in Thoracic Cancer
Verified
Journal Article
Open access
PDF file
TITakaya Ikeda
Takaya Ikeda
HYHiroyuki Yamaguchi
Hiroyuki Yamaguchi
YDYosuke Dotsu
Yosuke Dotsu
HTHirokazu Taniguchi
Hirokazu Taniguchi
HGHiroshi Gyoutoku
Hiroshi Gyoutoku
HMHiroshi Mukae
Hiroshi Mukae
Nivolumab, an anti‐PD‐1 antibody, has been shown to be effective in many cancers, such as malignant melanoma and lung cancer; however, nivolumab therapy can result in pseudoprogression. Diffuse alveolar hemorrhage (DAH) is persistent or recurrent pulmonary hemorrhage as a result of drugs, autoimmune diseases, or infections. DAH with pseudoprogression during nivolumab administration has rarely been reported. Herein, we describe our experience with one such case. A 41‐year‐old woman exhibited bloody sputum and ground glass opacities in the lungs along with tumor growth during nivolumab therapy for multiple lung metastases of malignant melanoma. We diagnosed DAH with pseudoprogression as a result of nivolumab and administered steroid therapy. The DAH subsequently improved and the tumor shrank. This case illustrates that nivolumab can cause DAH with pseudoprogression, which can be controlled by steroid therapy. Thus, if bloody sputum and ground glass opacities in the lungs are observed with tumor growth during nivolumab administration, steroid therapy should be considered to control DAH with pseudoprogression.

10 October 2024 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
SUShigeki Umemura
Shigeki Umemura
HUHibiki Udagawa
Hibiki Udagawa
TITakaya Ikeda
Takaya Ikeda
HMHaruyasu Murakami
Haruyasu Murakami
HDHaruko Daga
Haruko Daga
KGKoichi Goto
Koichi Goto

9 January 2019 in Thoracic Cancer
Verified
Journal Article
Open access
PDF file
STShinnosuke Takemoto
Shinnosuke Takemoto
YNYoichi Nakamura
Yoichi Nakamura
HGHiroshi Gyoutoku
Hiroshi Gyoutoku
HSHiroaki Senju
Hiroaki Senju
DODaiki Ogawara
Daiki Ogawara
HMHiroshi Mukae
Hiroshi Mukae
Background: We prospectively evaluated the efficacy and toxicity of a non‐platinum triplet regimen for patients with advanced non‐small cell lung cancer (NSCLC) expected to be platinum‐resistant.Methods: Patients were diagnosed with NSCLC using endobronchial ultrasonography with a guide sheath as a core biopsy. RNA was immediately isolated from unfixed biopsy specimens, and quantitative real‐time reverse transcription‐PCR assays were performed to determine ERCC1 messenger RNA expression. Patients with advanced, untreated NSCLC showing high ERCC1 levels (ΔCt ≧ 6.5) were assigned a non‐platinum triplet regimen of irinotecan and paclitaxel plus bevacizumab. The primary end point was the objective response rate (ORR).Results: A total of 141 untreated patients were evaluated and 30 patients were entered into this phase II trial. The ORR was 66.7% (95% confidence interval [CI] 47.2–82.7) and median progression‐free survival (PFS) was 215 days. Grade 4 thrombosis occurred in one patient, but other toxicities were mild and controllable. Fifty‐six patients were treated with platinum‐containing regimens and 24 patients responded (ORR 42.8%, 95% CI 29.7–56.7). Twenty‐nine of these patients had high ERCC1 levels, of which 6 patients responded; 27 patients had low ERCC1 levels, 18 patients responded (P = 0.0053 by Fisher’s exact test).Conclusion: The triplet combination might be effective for patients with advanced, untreated NSCLC overexpressing ERCC1. ERCC1 messenger RNA levels may be a predictive factor for response to platinum‐containing regimens.

28 May 2020 in Thoracic Cancer
Verified
Journal Article
Open access
PDF file
TITakaya Ikeda
Takaya Ikeda
STShinnosuke Takemoto
Shinnosuke Takemoto
HSHiroaki Senju
Hiroaki Senju
HGHiroshi Gyotoku
Hiroshi Gyotoku
HTHirokazu Taniguchi
Hirokazu Taniguchi
HMHiroshi Mukae
Hiroshi Mukae
Background: The aim of this study was to assess the efficacy and safety of amrubicin for previously treated malignant pleural mesothelioma.Methods: The eligibility criteria were: previously treated unresectable malignant pleural mesothelioma; performance status 0–1; age ≤ 75; adequate hematological, hepatic, and renal function. The patients were injected with 35 mg/m2 amrubicin on days one, two, and three every 3–4 weeks. The planned number of patients was 32.Results: The study was terminated due to delay in enrollment and 10 patients were subsequently enrolled (nine males and one female; median age 67 [range 49–73]), of which four had epithelioid tumors, three had sarcomatoid tumors and three had biphasic tumors, respectively. According to the International Mesothelioma Interest Group (IMIG), one, four, and four patients had stage II, III, and IV, respectively, and one had postoperative recurrence. There was one (10%) partial response, four (40%) had stable disease, and five (50%) patients exhibited disease progression. The overall response and disease control rates were 10% (95% CI: 0.3–44.5%) and 60% (95% CI: 26.2–87.8%), respectively. The median progression‐free survival time was 1.6 months. The median overall survival time was 6.6 months, and the one‐, two‐, and three‐year survival rates were 23%, 23%, and 0%, respectively. The observed grade 3 or 4 toxicities included neutropenia in six (60%) patients; leukopenia in five (50%) patients; and febrile neutropenia, thrombocytopenia, anemia, and pneumonia in one (10%) patient each.Conclusions: There was not enough data to evaluate the efficacy because the study was terminated early. However, amrubicin showed limited activity andacceptable toxicities when used in previously treated malignant pleural mesothelioma patients.

16 July 2019 in Thoracic Cancer
Verified
Journal Article
Open access
PDF file
HTHirokazu Taniguchi
Hirokazu Taniguchi
HYHiroyuki Yamaguchi
Hiroyuki Yamaguchi
YDYosuke Dotsu
Yosuke Dotsu
MSMidori Shimada
Midori Shimada
HGHiroshi Gyotoku
Hiroshi Gyotoku
HMHiroshi Mukae
Hiroshi Mukae
Background: The first‐line treatment for squamous cell lung cancer (SCC) has not necessarily been established; however, our previous exploratory study suggested that the combination of nedaplatin and amrubicin would be a promising treatment approach for patients with SCC. Therefore, a phase II study of this chemotherapeutic combination was designed to evaluate its efficacy and safety for treatment‐naïve patients with advanced SCC.Methods: A total of 21 treatment‐naïve patients with stage IIIB/IV or postoperative recurrent SCC were enrolled from six institutions. Nedaplatin (100 mg/m2) on day 1 and amrubicin (25 mg/m2) on days 1–3 were administered intravenously every 4 weeks. The primary endpoint was overall response rate (ORR), while the secondary endpoints included overall survival (OS), progression‐free survival (PFS), and drug toxicities.Results: Partial response was observed in seven of 21 cases (ORR, 33.3%; 95% confidence interval [CI], 14.5–52.2). Disease control rate, which includes stable disease, was 71.4%. Median OS and PFS was 14.6 and 4.1 months, respectively. This regimen did not cause any treatment‐related deaths. Grade 3/4 neutropenia developed in 8 of 21 cases (38.1%); however, febrile neutropenia developed in only 9.5% of the cases. Grade 3/4 gastrointestinal or neuromuscular toxicities were not observed.Conclusion: The efficacy of the combination of nedaplatin and amrubicin was comparable to that of other conventional chemotherapeutic regimens for treatment‐naïve patients with advanced SCC, and no severe gastrointestinal or neuromuscular toxicities were observed. This combination therapy may be an alternative treatment approach, particularly in patients who cannot tolerate gastrointestinal or neuromuscular toxicities.

1 January 2012 in Haigan
Verified
Journal Article
Closed access
PDF file
TITakaya Ikeda
Takaya Ikeda
YNYoichi Nakamura
Yoichi Nakamura
MFMinoru Fukuda
Minoru Fukuda
MFMasaaki Fukuda
Masaaki Fukuda
HSHiroshi Soda
Hiroshi Soda
SKShigeru Kohno
Shigeru Kohno
目的.悪性胸膜中皮腫に対するペメトレキセドを含む化学療法の効果と有害事象についてレトロスペクティブな検討を行った.方法.2007年2月~2009年12月に長崎胸部腫瘍研究グループ関連施設においてペメトレキセドを含む化学療法を行った悪性胸膜中皮腫34例を検討.結果.男性28例,女性6例,年齢中央値68歳(53~81歳)でアスベスト曝露があった症例は26例.病理組織型は上皮型16例,肉腫型10例,二相型5例,不明3例であった.初回化学療法25例,既治療8例,30例がペメトレキセド・シスプラチン併用療法,3例がペメトレキセド・カルボプラチン併用療法,1例がペメトレキセド単剤療法を受けていた.ペメトレキセド(500 mg/m2)・シスプラチン(75 mg/m2)併用療法を受けた24例のGrade 3以上の毒性は白血球減少2例(8.3%),好中球減少5例(20.8%),消化器毒性2例(8.3%)で,奏効率12.5%,生存期間中央値14.4ヶ月であった.結論.実臨床でのペメトレキセド・シスプラチン併用療法の効果と有害事象は,過去の前向き試験の結果とほぼ同程度であった.